Literature DB >> 20304710

[Age of menopause in patients with differentiated thyroid cancer treated with radioiodine].

Juan Manuel García-Quirós Muñoz1, Tomás Martín Hernández, Alberto Torres Cuadro, Teresa Cambil Molina, Juan Castro Montaño, Angel Sendón Pérez.   

Abstract

INTRODUCTION: Differentiated thyroid cancer (DTC) is an increasingly frequent endocrinological disease. Radioiodine is a key component of treatment.
OBJECTIVE: To analyze the effects of I(131) therapy on ovarian and reproductive function.
MATERIAL AND METHODS: We retrospectively analyzed data from 202 women treated with radioiodine for DTC in our service from 1985-2008. Data on age at menopause in patients and their mothers and sisters, menstrual history, fertility and neonatal abnormalities were collected.
RESULTS: Menopause occurred in 34 patients at follow-up. The mean age at menopause in patients was 49.94+/-3.45 while that in their mothers and sisters was 49.20+/-5.37 and 48.73+/-3.74 years, respectively. Three patients had transient amenorrhea. No infertility or neonatal alterations were found.
CONCLUSIONS: In our series, menopause did not occur earlier in patients than in their first degree relatives. No significant alterations in neonatal health, fertility or menstruation were found. Copyright 2009 SEEN. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304710     DOI: 10.1016/j.endonu.2010.01.014

Source DB:  PubMed          Journal:  Endocrinol Nutr        ISSN: 1575-0922


  2 in total

1.  Anti-Müllerian hormone in pre-menopausal females after ablative radioiodine treatment for differentiated thyroid cancer.

Authors:  Massimo Giusti; Miranda Mittica; Paola Comite; Claudia Campana; Stefano Gay; Michele Mussap
Journal:  Endocrine       Date:  2018-01-04       Impact factor: 3.633

2.  Pregnancy Outcome After I-131 Therapy for Patients With Thyroid Cancer: A Nationwide Population-Based Cohort Study.

Authors:  Kuan-Yin Ko; Ruoh-Fang Yen; Cheng-Li Lin; Mei-Fang Cheng; Wen-Sheng Huang; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.